GSK126 Work It Is Possible To Complete By Yourself

15-18 Bevacizumab has antitumor activity in a broad spectrum of tumors, and it improves survival in metastatic colorectal cancer. Therefore, we conducted a phase 1 study of HAI oxaliplatin combined with systemic 5-FU/leucovorin and bevacizumab in patients with advanced solid tumors metastatic to the liver. The primary objectives were to determine the dose-limiting toxicity (DLT) and maximum tolerated http://www.selleck.cn/products/gsk126.html dose (MTD) of oxaliplatin and to assess toxicity. We also assessed response or clinical benefit, if any. From August 2006 to November 2008, 57 patients were treated on protocol. Eligibility criteria included patients who were seen in the Phase 1 Clinical Trials Program at The University of Texas M. D. Anderson Cancer Center with histologically confirmed, advanced cancer (any type) and liver metastases who had failed at least 1 prior chemotherapy regimen. Other eligibility criteria included an Eastern Cooperative Oncology Group performance status between 0 and 2; at least 3 weeks after completion of previous therapy; baseline toxicity grade ��1; and adequate renal (serum creatinine ��2.0 mg/dL), hepatic (total bilirubin ��3 mg/dL, aspartate transaminase or alanine transaminase level ��5 times the upper normal reference value), and bone marrow function (absolute neutrophil count ��1.5 �� 109/L; platelet count ��100 �� 109/L). Patients were excluded because of pregnancy; peripheral neuropathy (grade ��2); serious wound; history http://www.selleckchem.com/products/Cyclopamine.html of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess; major surgical procedure within 28 days before therapy; bleeding diathesis; active gastric/duodenal ulcer; uncontrolled intercurrent illness or hypertension; 24-hour urine protein >1 g; history of cerebrovascular accident within the past 6 months; myocardial http://www.selleckchem.com/products/BI-2536.html infarction/unstable angina within the past 6 months, New York Heart Association grade ��2 congestive heart failure, serious cardiac arrhythmia, and clinically significant peripheral vascular disease; or history of bleeding brain metastasis. Before enrollment, all participants signed informed consent forms that fully disclosed the investigational nature of the trial. Patients aged